A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene AutoleucelFirst published 24/10/2022 Last updated 12/06/2025 EU PAS number: EUPAS49218StudyOngoing